ADVANCED MALIGNANT SOLID NEOPLASM

This study is testing a drug called defactinib for people with advanced cancers that have a specific genetic change called an NF2 mutation. The drug aims to block a protein that these cancer cells may need to grow. Researchers want to see if taking defactinib pills twice a day ca…

This study is testing whether a pill called palbociclib can shrink or stop the growth of advanced cancers that have specific genetic changes (CCND1, 2, or 3 amplification). The drug works by blocking proteins that help cancer cells grow. The trial is for adults with advanced soli…

This study is testing a new oral drug called TRC102 (methoxyamine) to see if it can make tumor cells more sensitive to standard chemotherapy drugs. It is for adults with advanced solid tumors or mesothelioma that have spread or stopped responding to usual treatments. The goal is …

This early-phase trial is testing a new way of giving two cancer drugs—olaparib and adavosertib—one after the other instead of together. The goal is to see if this sequence can shrink or stabilize advanced solid tumors that have spread and stopped responding to other treatments, …

This study is testing a new combination of three drugs—copanlisib, nivolumab, and ipilimumab—for adults with advanced solid tumors that have spread and have specific genetic changes. The goal is to see if adding copanlisib to two existing immunotherapy drugs is safe and works bet…

This study is testing an oral drug called MLN0128 (TAK-228) in patients with advanced or hard-to-treat cancers that have specific genetic changes called mTOR mutations. The drug is designed to block a key enzyme that cancer cells need to grow. The goal is to see if the drug can s…

This study is testing whether the drug crizotinib can help people with advanced cancers that have a specific genetic change called a ROS1 translocation. The drug aims to block a protein that these cancer cells need to grow. Researchers want to see if taking crizotinib daily can s…

This study is testing whether a drug called ado-trastuzumab emtansine can shrink or stop the growth of advanced cancers that have a specific genetic change called HER2 amplification. The trial is for patients with various hard-to-treat cancers (like lymphoma and solid tumors), bu…

This early-stage study is testing the safety and best doses of a drug called neratinib when given with one of three other drugs (everolimus, palbociclib, or trametinib). It is for adults with advanced solid tumors that have specific genetic mutations and have stopped responding t…

This early-stage study is testing the safety and best dose of two drugs, veliparib and dinaciclib, when given together to patients with advanced solid tumors that have spread. The main goal is to find out what side effects occur and determine a safe dose for future testing. The d…

This study is testing whether a drug called copanlisib can help control advanced cancers that have a specific change in a gene called PTEN. The drug is given through an IV and aims to block signals that tell cancer cells to grow. It is for adults with various advanced or hard-to-…

This study is testing whether a pill called afatinib can help control advanced cancers that have a specific genetic change (EGFR mutation) and have stopped responding to standard treatments. It is for adults with various solid tumors or lymphomas (but not lung cancer or certain b…

This is an early-stage safety study testing a new drug called BAY 1895344 when given with standard chemotherapy drugs (cisplatin with or without gemcitabine). The main goals are to find the safest dose and understand the side effects in people with advanced solid tumors that have…

This study is testing whether the drug crizotinib can help control advanced cancers that have a specific genetic change called a MET exon 14 deletion. It is for patients with solid tumors, lymphoma, or multiple myeloma that have stopped responding to other treatments. Participant…

This study is testing an experimental drug called AZD5363 in patients with advanced cancers that have a specific genetic change called an AKT mutation. The drug is designed to block the AKT protein, which cancer cells need to grow. Researchers want to see if taking this pill can …

This trial is testing a combination of three drugs (niraparib, temozolomide, and atezolizumab) to see if they work better together to control advanced cancers. The study first finds the safest dose, then compares the three-drug combo to a single drug for patients with extensive-s…

This early-stage study is testing the safety and best dose of a new two-drug combination (ZEN003694 and binimetinib) for people with advanced solid tumors that have specific genetic changes. The main goal is to see what side effects occur and find a dose that is safe for future t…

This study is testing a drug called sunitinib in patients with advanced cancers that have a specific change (mutation) in a gene called cKIT. The drug aims to block the faulty signal from this mutated gene that tells cancer cells to grow, which could help slow or stop the cancer'…

This study is testing an experimental pill called telaglenastat in adults with advanced solid tumors that have spread or cannot be removed by surgery. The pill works by blocking a nutrient (glutamine) that some cancer cells with specific genetic mutations need to grow. The goal i…

This study is testing an oral drug called MLN0128 (TAK-228) in patients with advanced cancers that have stopped responding to other treatments. The drug is specifically for patients whose tumors have certain genetic changes called TSC1 or TSC2 mutations. The goal is to see if blo…

This study is testing whether the drug taselisib can shrink or stop the growth of advanced cancers that have a specific genetic change called a PIK3CA mutation. It is for patients whose cancer has not responded to standard treatments. The goal is to see if blocking the faulty PIK…

This is an early safety study testing a new type of intravenous drug called EphA2 siRNA in patients with advanced solid tumors that have spread or returned after treatment. The drug is designed to slow cancer growth by 'silencing' a specific gene that helps tumors grow. The main …

This study is testing whether the drug vismodegib can help control advanced cancers that have specific genetic mutations and have stopped responding to standard treatments. The trial includes 35 adults with solid tumors, lymphoma, or multiple myeloma that have spread or are resis…

This study is testing an experimental pill called GSK2636771 for people with advanced cancers that have stopped responding to other treatments and have a specific genetic change called a PTEN mutation. The pill is designed to block a protein that these cancer cells may need to gr…

This study is testing a pill called trametinib for people with advanced cancers that have stopped responding to other treatments and have specific changes in a gene called BRAF. The pill aims to block proteins that these cancer cells need to grow. Researchers want to see if the t…

This study is testing a drug called larotrectinib in children and young adults (ages 1-21) whose advanced solid tumors, lymphomas, or histiocytic disorders have returned or not responded to standard treatments. The drug is given to patients whose tumors have a specific genetic ch…

This study is testing whether a drug called copanlisib can shrink or stop the growth of advanced cancers that have a specific genetic change called a PIK3CA mutation. The drug works by blocking a protein that cancer cells need to grow. The trial includes 35 adults with various ad…

This study is testing a drug called trametinib for people with advanced cancers that have a specific genetic change called an NF1 mutation. The drug works by blocking proteins that these cancer cells may need to grow. Researchers want to see if trametinib can shrink these tumors …

This early-stage trial is testing a new combination of three drugs—dasatinib, temsirolimus, and cyclophosphamide—to treat advanced solid tumors that have come back or stopped responding to other treatments. The main goal is to find the safest dose and understand the side effects.…

This study is testing a targeted drug called erdafitinib in patients with advanced cancers that have a specific genetic change (FGFR amplification). The drug works by blocking a faulty protein that tells cancer cells to grow. The trial aims to see if the drug can shrink tumors or…

This early-stage trial is testing whether combining an experimental cancer drug called MK-2206 with the malaria drug hydroxychloroquine is safe for people with advanced solid tumors, melanoma, kidney, or prostate cancer. The main goal is to find the highest dose patients can tole…

This early-stage study is testing a new combination of two drugs, AZD8186 and docetaxel, for patients with advanced solid tumors that have specific genetic changes (PTEN or PIK3CB mutations). The main goals are to find the safest and most effective dose and to understand the side…

This study is testing whether the drug olaparib can help control advanced cancers that have a specific genetic change (IDH1 or IDH2 mutation) and have stopped responding to standard treatments. It is enrolling adults with certain brain tumors, bile duct cancer, or other solid tum…

This study is testing if the drug trametinib can help control advanced cancers that have specific genetic changes called GNAQ or GNA11 mutations. It is for patients with various cancers, including solid tumors and lymphomas, that have not responded to other treatments. The goal i…

This early-stage study is testing the safety and best dose of two drugs, riluzole and sorafenib, when given together. It's for people with advanced solid tumors or melanoma that have spread and are no longer responding to standard treatments. The goal is to see if this combinatio…

This is a small, early-stage safety study testing a combination of two cancer drugs, nivolumab and cabozantinib, in people living with HIV who have advanced solid tumors. The main goal is to see if the two-drug combination is safe and tolerable for this specific patient group. Re…

This is an early-stage study to find the safest dose of two oral drugs, cabozantinib and pamiparib, when given together. It is for adults with advanced solid tumors that have spread or stopped responding to standard treatments. The goal is to see if blocking multiple cancer growt…

This study is testing whether taking two oral drugs, cediranib and olaparib, together can help control advanced cancers that have spread or cannot be surgically removed. It is for adults with specific types of advanced lung, breast, or pancreatic cancer who have already tried at …

This study tested whether the immunotherapy drug pembrolizumab could help control the growth of rare, advanced cancers that have spread or cannot be removed by surgery. It involved 157 patients with specific rare tumor types who had already tried standard treatments. The goal was…

This trial is testing whether the drug crizotinib can help control advanced cancers that have a specific genetic change called MET amplification. It is for adults with solid tumors, lymphoma, or multiple myeloma that have stopped responding to other treatments. The drug works by …

This study is testing whether a drug called afatinib can help people with advanced cancers that have a specific genetic change called a HER2 mutation. The drug works by blocking a protein that helps cancer cells grow. Researchers are enrolling about 40 patients whose cancers have…

This study is testing a drug called ensartinib in children and young adults whose advanced cancers have specific genetic changes (ALK or ROS1). The goal is to see if the drug can shrink tumors or stop them from growing in patients whose cancer has come back or hasn't responded to…

This study is testing the safety and effectiveness of avelumab, an immunotherapy drug, when given in combination with other immune-boosting drugs and sometimes radiation. It is for patients with advanced solid tumors that have spread and who have run out of standard treatment opt…

This study is testing a personalized treatment method for people with advanced breast, prostate, ovarian, pancreatic, or sarcoma cancers that have spread. Doctors analyze each patient's tumor using genetic and protein tests to understand how the cancer is changing and which drugs…

This study is testing an oral drug called ulixertinib in children and adolescents whose advanced cancers have not responded to standard treatments and have a specific genetic change in a cell pathway called MAPK. The main goal is to see if the drug can shrink tumors and control t…

This study is testing whether two drugs, dabrafenib and trametinib, can shrink or stop the growth of advanced cancers that have a specific genetic change called a BRAF V600 mutation. It is for patients with solid tumors, lymphoma, or multiple myeloma that have not responded to ot…

This large national trial is testing whether choosing cancer drugs based on the specific genetic changes found in a patient's tumor is more effective than standard approaches. It is for adults with advanced solid tumors, lymphoma, or multiple myeloma that have progressed after at…

This trial is testing whether the drug osimertinib can help control advanced cancers that have specific changes (mutations) in a gene called EGFR. The drug works by blocking the faulty protein these mutations create, which may slow or stop cancer growth. The study is for adults w…

This study is testing a personalized approach for children and young adults with advanced cancers that have come back or stopped responding to standard treatments. Doctors first test the genetic makeup of a patient's tumor to look for specific changes. If a matching change is fou…

This trial is testing an oral drug called ulixertinib in patients with advanced cancers that have specific, less common changes in a gene called BRAF. The drug aims to block signals that tell cancer cells to grow, potentially slowing or stopping the disease. It is for patients wi…

This study is testing if the drug crizotinib can shrink or stop the growth of advanced cancers that have a specific genetic change called an ALK rearrangement. It is for people with various solid tumors or blood cancers (excluding certain lung cancers and lymphomas) that have not…

This early-stage study is testing a new drug, ALRN-6924, combined with a standard chemotherapy (paclitaxel) for people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find the safest and most effective dose of this combination an…

This study is testing how well the drug palbociclib works for patients with advanced cancers that have not responded to other treatments and have specific changes in their CDK4 or CDK6 genes. The drug aims to block signals that tell cancer cells to grow, potentially slowing or st…

This study is testing a drug called erdafitinib in children and young adults with advanced cancers that have returned or not responded to standard treatments. It is for patients whose tumors have specific genetic changes (FGFR mutations). The goal is to see if the drug, which is …

This study is testing a drug called binimetinib in patients with advanced cancers that have a specific genetic change called an NRAS mutation. The drug works by blocking proteins that cancer cells with this mutation need to grow. Researchers want to see if the drug can shrink the…

This trial is testing whether a pill called ipatasertib can help control advanced cancers that have stopped responding to other treatments and have a specific genetic change called an AKT mutation. About 35 patients with various advanced cancers, including solid tumors, lymphoma,…

This study is testing whether the drug AZD1775 can shrink or stop the growth of advanced cancers that have specific genetic changes called BRCA1 or BRCA2 mutations. The drug works by blocking a protein called WEE1 that these cancer cells may need to survive. The trial will involv…

This study is testing an experimental pill called GSK2636771 for people with advanced cancers that have stopped responding to other treatments. The drug is specifically for cancers that have completely lost a protein called PTEN. Researchers want to see if the pill can shrink the…

This trial is testing how well the drug larotrectinib works for people with advanced cancers that have a specific genetic change called an NTRK fusion. The drug is designed to block the abnormal protein made by this gene change, which may slow or stop cancer growth. The study is …

This early-stage trial is testing a combination of three drugs—copanlisib, olaparib, and durvalumab—in patients with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to find the safest and most effective dose of this combination for people …

This study tests whether virtual group therapy can help caregivers of patients with advanced cancer or serious illnesses. Caregivers often feel overwhelmed, hopeless, and lose their sense of purpose. The therapy aims to help them reconnect with meaning and reduce their emotional …

This study is testing a mindfulness program specially adapted for Latino culture to help patients with advanced cancer and their family caregivers. The program teaches awareness of thoughts and feelings to reduce stress and anxiety related to a cancer diagnosis. Participants are …

This study is testing whether adding weekly technology-based symptom check-ins to standard palliative care visits helps improve quality of life and symptom control for patients with advanced cancer. The trial involves 119 patients who are already enrolled in early-stage (Phase I)…

This study is testing if an 'open-label' placebo—a sugar pill that patients know contains no medicine—can help reduce severe fatigue in people with advanced cancer. About 100 participants with significant fatigue were randomly assigned to either start taking the placebo pills rig…

This study is testing whether a combination of home-based exercise and a short course of a steroid medication (dexamethasone) can help reduce severe fatigue in people with advanced cancer. The trial involves 99 participants who will be randomly assigned to do exercise with either…

This study is testing whether a drug called anamorelin, combined with a home exercise program and nutritional counseling, can help reduce severe fatigue in people with advanced, incurable solid tumors. Participants take the drug daily for 6 weeks while following the exercise and …

This study is testing two different ways to help cancer clinics provide a phone-based support program called ENABLE to patients with advanced cancer and their caregivers. The program focuses on improving quality of life by helping with stress, symptoms, communication, and plannin…

This study is testing whether having a team of cancer genetics experts review a patient's tumor test results helps doctors choose more effective treatments. It compares the usual approach where doctors review results alone against having a special 'genomic tumor board' provide ex…

This study aims to understand how often advanced cancer patients experience severe weight loss and loss of appetite, a condition called cachexia. Researchers are also measuring the emotional and psychological stress this causes for both the patients and their primary family careg…

This study aims to understand how people with advanced cancer think about and plan for what happens to their social media accounts (like Facebook or Instagram) after they die. Researchers surveyed 117 patients in a supportive care clinic to learn if they've discussed this with fa…

This is an early, small study to understand how the drug DS-8201a works in the body of patients with advanced HER2-positive cancers. Researchers are giving the drug to 62 patients and taking small tumor samples before and after treatment to see how it affects cancer cells and the…